KR102130010B1 - Primer set of transforming growth factors beta for detecting immunization of fish - Google Patents

Primer set of transforming growth factors beta for detecting immunization of fish Download PDF

Info

Publication number
KR102130010B1
KR102130010B1 KR1020190012152A KR20190012152A KR102130010B1 KR 102130010 B1 KR102130010 B1 KR 102130010B1 KR 1020190012152 A KR1020190012152 A KR 1020190012152A KR 20190012152 A KR20190012152 A KR 20190012152A KR 102130010 B1 KR102130010 B1 KR 102130010B1
Authority
KR
South Korea
Prior art keywords
leg
immunization
fish
immunogen
pcr
Prior art date
Application number
KR1020190012152A
Other languages
Korean (ko)
Inventor
안경진
이주형
김민지
양희경
Original Assignee
주식회사 준원지비아이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 준원지비아이 filed Critical 주식회사 준원지비아이
Priority to KR1020190012152A priority Critical patent/KR102130010B1/en
Application granted granted Critical
Publication of KR102130010B1 publication Critical patent/KR102130010B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a TGF beta primer set for confirming immunization of fish. By using the primer set to easily confirm the immune status of Platichthys stellatus immunized with an attenuated vaccine, management and confirmation of the health status of Platichthys stellatus in a farm thereof can be performed more efficiently than before.

Description

어류의 면역화 확인용 TGF 베타 프라이머 세트 {Primer set of transforming growth factors beta for detecting immunization of fish}TGF beta primer set for immunization of fish {Primer set of transforming growth factors beta for detecting immunization of fish}

본 발명은 어류의 면역화 확인용 어류의 면역화 확인용 TGF-β(transforming growth factors β) 프라이머 프라이머 세트에 관한 것이다. The present invention relates to a TGF-β (transforming growth factors β) primer primer set for immunization verification of fish for immunization verification of fish.

전 세계 동물용 백신 시장이 매년 2~3%씩 성장하고 있으며, 2015년 56억달러 규모인 것으로 보고된 바 있다. 우리나라의 경우, 전체 동물용 의약품시장은 6,000억원 정도로 예측하며, 그 중 수산용 의약품은 500억정도로 추산된다. 그러나, 수산용의 경우 기존의 축산용의 항생제를 사용하지 않도록 강력하게 규제하거나, 수산질병관리사의 역할을 증대시켜 관리를 하도록 유도하고 있지만, 항생제의 대체제나 항생제의 사용을 저감 할 근본적인 대책이 마련되고 있지 않은 실정이다. 백신은 항원을 체내에 주입하는 방식으로 알려져 있으며, 다양한 방법이 개발되어져 왔으나 많이 개발되지 않은 상황이고 현재 백신사용이 항생제 오남용을 저감시키는 유일한 방법으로 알려져 있다.The worldwide vaccine market for animals is growing 2-3% per year, and is reported to be $5.6 billion in 2015. In Korea, the total veterinary drug market is estimated at about 600 billion won, of which the fishery drug is estimated to be about 50 billion won. However, in the case of fisheries use, it is strongly regulated not to use the antibiotics for livestock production, or it is encouraging management by increasing the role of the fisheries disease manager, but fundamental measures to reduce the use of antibiotics or antibiotics are prepared. It is not being. Vaccines are known to inject antigens into the body, and various methods have been developed, but many have not been developed, and vaccine use is currently known as the only way to reduce antibiotic abuse.

한편, 기존의 수산동물들을 위한 백신은 모두 주사백신이며, 한 마리씩 주사하여야 하는 노동력을 감수해야 하는 형태이다. 그러나 국내에는 수산질병관리사의 현장 입회와 접종 시 인원의 부재로 많은 시간에 비해 작업량이 적어 어가의 실제적인 도움을 주지 못하고 있는 실정이다. 따라서, 주사보다는 간편하고 훨씬 사용하기 용이한 경구형태의 백신이 시급하다.On the other hand, all existing vaccines for aquatic animals are injection vaccines, and are in the form of taking the labor force to inject one by one. However, in Korea, due to the absence of personnel during on-site attendance and inoculation of fisheries disease managers, the amount of work is small compared to many hours, and thus, it is not possible to provide practical help for fishery. Therefore, there is an urgent need for an oral vaccine that is simpler and easier to use than injection.

최근까지 연구되고 있는 경구형태의 백신은 간편한 용이성 대신 효능의 증감을 기대하기가 쉽지 않다. 또한, 사료와 함께 투여하는 장점에 비해 허실이 많아서 제대로 복용이 될 수 있느냐의 문제까지 대두될 수 있다. 이러한 문제를 해결할 수 있는 부분은 경구용 제제에 백신균주를 나노공학적으로 탑재하고, 고정하는 기술을 개발하여 투여량을 정량화할 수 있는 기술이 아주 중요하다고 할 수 있다.Oral vaccines, which have been studied until recently, are not easy to expect to increase or decrease efficacy instead of ease. In addition, compared to the advantages of administering it with the feed, there are a lot of deficiencies, so the question of whether it can be taken properly can be raised. The part that can solve these problems is that it is very important to develop a technology for nano-engineering and immobilizing vaccine strains in oral preparations to quantify the dosage.

주사백신을 비즈의 형태로 제작하여 약독화된 미생물을 탑재할 경우에 집중적이고 유효농도의 산정을 용이하게 하는 등 다양한 백신을 이루어 제작할 수 있는 장점을 활용할 수 있다. 또한 각 백신에 대한 백신 접종 후 백신 효용에 대한 유전적 마커(genetic marker) 개발이 필요 경구백신을 개발하기 위해서는 점막면역과 장에서의 발현여부를 진단하는 유전적인 마커의 개발도 필요한 실정이다. When the injection vaccine is manufactured in the form of beads and loaded with attenuated microorganisms, it is possible to utilize the advantages of producing various vaccines such as intensive and easy calculation of effective concentration. In addition, it is necessary to develop a genetic marker for vaccine efficacy after vaccination for each vaccine. To develop an oral vaccine, it is also necessary to develop a genetic marker for diagnosing mucosal immunity and intestinal expression.

강도다리(starry flounder/diamond back, Platichthys stellatus)는 가자미목 가자미과의 바닷물고기로서 몸길이는 40cm 정도이고 둥근 마름모꼴이다. 눈은 보통 몸의 왼쪽에 있다. 등지느러미, 뒷지느러미, 꼬리지느러미에 여러 개의 흑색 띠가 있다. 눈 있는 쪽 색깔은 짙은 갈색, 눈 없는 쪽은 연한 노란색을 띤다. 다른 가자밋과 어류와 다르게 눈의 위치는 넙치와 같은 위치에 몰려 있다. 수심 150m내외의 연안역 저층에 서식하며, 종종 하천에 출현하기도 한다. 소형 갑각류, 연체류, 갯지렁이류 등을 먹고 2-3월에 강어귀에 알을 낳으며 우리나라 동해 북부에 출현한다. 일본 북부, 오호츠크 해, 베링 해, 캘리포니아 남부 등지에 분포하며 회, 건어물, 찜, 구이 등으로 이용한다. The starry flounder/diamond back ( Platichthys stellatus ) is a saltwater fish of the flatfish flounder. It is about 40 cm long and has a round lozenge. The eyes are usually on the left side of the body. There are several black bands on the dorsal fin, back fin, and caudal fin. The eye side color is dark brown, and the eye side is light yellow. Unlike other gazami and fish, the eye position is concentrated in the same position as the flounder. Inhabits the lower layers of coastal areas around 150m in depth and often appears in rivers. It eats small crustaceans, mollusks, and worms, and lays eggs in estuaries in 2-3 months, appearing in the northern part of the East Sea of Korea. It is distributed in the northern part of Japan, the Sea of Okhotsk, the Bering Sea, and southern California.

강도다리는 넙치보다는 질병에 강한 어종으로 알려져 있기는 하지만 주로 양식을 통해 기르기 때문에 질병관리에 있어서 다양한 방법이 적용되어야 할 필요가 있다. 그러나 항생제나 화학약품 등의 남용보다는 강도다리 어종 자체의 면역력을 증진시키는 것이 필요하며, 이러한 면역력 증진이 된 상태를 확인해야 할 필요성 또한 대두되고 있다. Intensity legs are known to be more resistant to disease than flounder, but because they are mainly raised through farming, various methods of disease management need to be applied. However, rather than abuse of antibiotics or chemicals, it is necessary to improve the immunity of the vulture-legged fish species itself, and the need to confirm the state in which the immunity has been enhanced is also emerging.

이에 본 발명자들은 약독화된 미생물을 균주에 투입하고 이를 TGF-β(transforming growth factors β) 유전자의 발현을 통해 확인하는 방법을 제공함으로써 본 발명을 완성하였다. Accordingly, the present inventors completed the present invention by providing a method for confirming the attenuated microorganisms into strains and expressing them through the expression of TGF-β (transforming growth factors β) gene.

대한민국 등록특허 제10-1789182호 (발명의 명칭 : 어류의 세균 감염 진단용 프라이머 세트 및 이를 이용한 어류의 세균 감염 진단 방법, 출원인 : 부산대학교 산학협력단, 등록일 : 2017년10월17일)Republic of Korea Registered Patent No. 10-1789182 (Invention name: Primer set for diagnosing bacterial infection of fish and method for diagnosing bacterial infection of fish using the same, Applicant: Pusan National University Industry-University Cooperation Foundation, Registration Date: October 17, 2017) 대한민국 공개특허 제10-2018-0106570호 (발명의 명칭 : 신규 스트렙토코커스 파라우베리스 균주의 방어 혈청형을 포함하는 강도다리 세균성 질병 예방용 불활성화 백신의 제조방법 및 투여방법, 출원인 : 주식회사 코미팜, 공개일 : 2018년10월01일)Republic of Korea Patent Publication No. 10-2018-0106570 (Name of the invention: Method and method for preparing and administering an inactivated vaccine for the prevention of bacterial disease of high-intensity legs containing a protective serotype of a new Streptococcus p. aureus strain, Applicant: Comi Farm, Release date: October 01, 2018)

본 발명의 목적은 어류의 면역화 확인용 TGF-β(transforming growth factors β) 프라이머 세트를 제공하는 데에 있다. An object of the present invention is to provide a set of TGF-β (transforming growth factors β) primers for immunization of fish.

본 발명은 서열번호 1 및 2의 프라이머를 포함하는 것을 특징으로 하는 어류의 면역화 확인용 프라이머 세트에 관한 것이다.The present invention relates to a primer set for immunization of fish characterized in that it comprises the primers of SEQ ID NO: 1 and 2.

상기 어류는 강도다리인 것을 특징으로 한다. The fish is characterized in that the strength leg.

본 발명은 상기 프라이머 세트를 이용한 어류의 면역화 확인 방법을 제공한다. The present invention provides a method for confirming immunization of fish using the primer set.

상기 어류의 면역화 확인 방법은, 바람직하게는, The method for confirming the immunization of the fish, preferably,

(제1단계) 강도다리에 면역원을 투여하는 단계; (제2단계) 면역원이 투여된 강도다리와 면역원이 비투여된 강도다리의 장을 각각 채취하여 mRNA(messenger Ribonucleic acid)를 추출하고 cDNA(complementary Deoxyribonucleic acid)를 합성하는 단계; (제3단계) 상기 cDNA와 본 발명의 프라이머 세트를 이용하여 PCR(Polymerase chain reaction)을 수행하는 단계; 및, (제4단계) 면역원이 투여된 강도다리와 면역원이 비투여된 강도다리의 유전자 발현량을 비교하는 단계;를 통해 수행되는 것을 특징으로 한다. (First step) administering an immunogen to the burglar leg; (2nd step) extracting mRNA (messenger ribonucleic acid) and synthesizing cDNA (complementary deoxyribonucleic acid) by extracting the intestine of the intensity leg to which the immunogen was administered and the intensity leg to which the immunogen was not administered; (Step 3) performing PCR (Polymerase chain reaction) using the cDNA and the primer set of the present invention; And, (4th step) comparing the gene expression level of the intensity leg to which the immunogen is administered and the intensity leg to which the immunogen is not administered is characterized by being performed through.

본 발명의 프라이머 세트에 포함되는 각각의 프라이머 서열은 하기와 같다. Each primer sequence included in the primer set of the present invention is as follows.

서열번호 1 (TGF-β의 프라이머 F) : TGGAAAGGAACTCGACCAACSEQ ID NO: 1 (primer F of TGF-β): TGGAAAGGAACTCGACCAAC

서열번호 2 (TGF-β의 프라이머 R) : AATGGGTCTCCTTCGATGTGSEQ ID NO: 2 (primer R of TGF-β): AATGGGTCTCCTTCGATGTG

또한 각 프라이머가 증폭하는 유전자의 Genbank No.는 다음과 같다.In addition, Genbank No. of the gene amplified by each primer is as follows.

TGF beta : XM_020097733.1TGF beta: XM_020097733.1

본 발명에서 강도다리의 시료는 강도다리의 조직 어느 것이든지 사용가능하며, 어류의 조직, 세포, 혈액 등이 사용가능하며, 상기 조직 중에서 바람직하게는 장 조직을 사용하는 것이 좋다. In the present invention, any sample of the strength leg may be used as any tissue of the strength leg, fish tissue, cells, blood, etc. may be used, and intestinal tissue is preferably used among the tissues.

본 발명에서 강도다리의 면역화에 사용될 수 있는 면역원으로는 강도다리의 면역 증진을 위해 사용될 수 있는 것이라면 어떤 것이라도 사용가능하나, 바람직하게는 Streptococcus parauberis, Vibrio harveyi 인 것이 좋다. 상기 면역원으로 사용된 균주는 더 바람직하게는 포르말린을 처리하여 약독화된 상태인 것이 더 좋다. In the present invention, any immunogen that can be used for immunization of the burglar leg can be used as long as it can be used to enhance the immunity of the burglar leg, preferably Streptococcus parauberis , Vibrio harveyi . The strain used as the immunogen is more preferably in an attenuated state by processing formalin.

상기 PCR은 실시간 RT-PCR(Real-time reverse transcript polymerase chain reaction) 또는 RT-PCR(Reverse transcript polymerase chain reaction)인 것을 특징으로 한다. The PCR is characterized in that it is a real-time real-time reverse transcript polymerase chain reaction (RT-PCR) or a reverse transcript polymerase chain reaction (RT-PCR).

상기 PCR이 실시간 RT-PCR일 경우, 형광 표지 인자로서 SYBR green이 추가될 수 있다. When the PCR is a real-time RT-PCR, SYBR green may be added as a fluorescent labeling factor.

본 발명의 방법에서 RNA로부터 cDNA를 합성할 때, 역전사효소, cNTPs 및 rNTP(사전 혼합형 또는 분리 공급형) 등이 이용될 수 있다.When synthesizing cDNA from RNA in the method of the present invention, reverse transcriptase, cNTPs and rNTP (pre-mixed or separate feed type) and the like can be used.

본 발명의 방법에서 PCR을 수행하기 위해, MgCl2, Tag DNA 폴리머라아제, dNTPs 등이 사용될 수 있다. To perform PCR in the method of the present invention, MgCl 2 , Tag DNA polymerase, dNTPs, and the like can be used.

본 발명은 어류의 면역화 확인용 어류의 면역화 확인용 TGF 베타 프라이머 세트에 관한 것으로서, 상기 프라이머 세트를 이용하여 약독화된 백신으로 면역화된 강도다리의 면역 상태를 용이하게 확인함으로써 강도다리 양식장에서 강도다리의 건강 상태에 대한 관리 및 확인을 기존보다 효율적으로 수행할 수 있게 되었다. The present invention relates to a set of TGF beta primers for immunization verification of fish for immunization verification of fish, and by using the primer set to easily check the immune status of the immunized leg immunized with the attenuated vaccine, the intensity leg in the intensity leg farm. It is now possible to efficiently manage and check the health status of a person.

이하 본 발명의 바람직한 실시예를 상세히 설명하기로 한다. 그러나, 본 발명은 여기서 설명되는 실시예에 한정되지 않고 다른 형태로 구체화될 수도 있다. 오히려, 여기서 소개되는 내용이 철저하고 완전해지도록, 당업자에게 본 발명의 사상을 충분히 전달하기 위해 제공하는 것이다. Hereinafter, a preferred embodiment of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms. Rather, it is provided to sufficiently convey the spirit of the present invention to those skilled in the art so that the contents introduced herein are thorough and complete.

<실시예 1. 어류의 면역화><Example 1. Immunization of fish>

본 발명에 사용한 강도다리는 주사백신을 둥근모양의 비즈를 형성하여 급이하였다. Intensity legs used in the present invention were injected with a vaccine to form round beads.

알긴산 0.5%(v/v) 수용액과 FKC(Streptococcus parauberis, Vibrio harveyi)(1×108 cfu/㎖)의 생리식염수(0.9%[w/v] NaCl) 용액을 1:1의 중량비로 혼합한 다음, 호스를 통해 정량펌프 (제조사 Gilson, 모델 : M312)에 투입하였다. 그 다음, 염화칼슘 0.5M 용액에 적하하여 비즈를 구성하였다. 이후 수온 18℃에서 강도다리에 초기 일주일은 1회(1알) 투여, 이후 2달에 3회 먹여 어류의 면역화를 유도하였다. Alginic acid 0.5% (v/v) aqueous solution and FKC ( Streptococcus parauberis , Vibrio harveyi ) (1×10 8 cfu/ml) physiological saline (0.9% [w/v] NaCl) solution in a weight ratio of 1:1 Next, it was put into a metering pump (manufacturer Gilson, model: M312) through a hose. Then, it was added dropwise to a 0.5 M solution of calcium chloride to construct beads. After that, the initial temperature was administered once a week (1 tablet) to the burglar legs at 18°C, and then fed 3 times every 2 months to induce immunization of fish.

강도다리는 각 실험구마다 10마리씩 사용하였으며, 면역화 정도는 비즈를 먹인 강도다리를 해부하여 장 조직을 채취한 뒤 조직 샘플에서의 각 유전자 발현량을 비교하였다. 본 실험에 사용한 균주는 Streptococcus parauberis는 제주의 넙치양식장에서 Vibrio harveyi는 경북지역 D 수산에서 직접 분리한 균주였고 각 형태와 유전학적 특성을 분석하여 균주의 동정이 완료된 것을 사용하였다. FKC는 각각의 생균의 농도를 1×108 cfu/㎖로 맞춘 뒤 0.2%(w/v) formalin 용액을 48시간 처리한 후 고체 영양배지에 다시 그어 colony를 형성하지 않은 것을 확인하여 모두 사멸하였음을 확인하고 난 후 비즈에 사용하였다. 포르말린 처리까지의 균주는 액체 영양배지에 배양된 상태로 처리되었고, 포르말린 용액의 용매로는 PBS(Phosphate Buffered Saline)를 사용하였다. Ten strength legs were used for each experimental group, and the degree of immunization was analyzed by dissecting the strength legs fed with beads, and then intestinal tissues were collected and the gene expression levels in the tissue samples were compared. The strain used in this experiment was Streptococcus parauberis in Jeju flounder farm, and Vibrio harveyi was a strain isolated directly from D fisheries in Gyeongbuk region. After adjusting the concentration of each live cell to 1×10 8 cfu/ml, the FKC was treated with 0.2% (w/v) formalin solution for 48 hours, and then re-drawn in a solid nutrient medium to confirm that colony was not formed and all of them were killed. After confirming, it was used for beads. The strain until formalin treatment was treated in a cultured state in a liquid nutrient medium, and PBS (Phosphate Buffered Saline) was used as a solvent for the formalin solution.

<실시예 2. 조직 적출과 RNA 분리 및 정제><Example 2. Tissue extraction and RNA isolation and purification>

강도다리의 장 면역마커 발현여부를 확인하기 위해 강도다리의 조직을 해부 한 뒤 장 조직을 적출하여 면역 부분이 많이 발현될 것이라 판단되는 뒷부분의 1/3지점을 잘라 사용하였다. 장 조직은 적출 즉시 안에 내용물을 빼고 1.5㎖ e-tube에 Ribosaver를 넣고 조직이 손상되지 않게 보관하였다. In order to confirm the expression of the intestinal immune marker of the burglar leg, the tissue of the burglar leg was dissected, and then the intestinal tissue was extracted to cut the 1/3 of the back of the part where it was determined that the immune part would be expressed. Immediately after extraction, the intestinal tissue was removed, and the Ribosaver was placed in a 1.5 ml e-tube, and the tissue was stored without damage.

RNA 분리는 Gene ALL(주) 회사의 Hybrid-R RNA 분리 kit를 사용하여 진행하였다. RNA isolation was performed using a Hybrid-R RNA isolation kit from Gene ALL.

이를 보다 자세히 설명하면, 1.5㎖ e-tube에 Ribo Ex 700㎕를 분주하고 마쇄 pestle를 이용하여 조직을 잘 갈아주었다. 후에 chloroform을 200㎕씩 넣고 상층액의 phenol 성분을 없애기 위해 충분히 vortexing 해 주었다. 원심분리기를 이용하여 (12000g에 4℃, 15분) 상층액을 딴 뒤 RB1 수용액을 상층액 만큼 넣어주고, 상층액과 RB1용액을 잘 섞어 준 뒤 Spin columm에 한방울씩 떨어트려 원심분리를 진행하였다(10000g에 20℃, 1분). 이후에 SW1 수용액과 RNW 수용액을 이용하여 워싱을 하고 free-water를 50㎕ 씩 천천히 넣어 원심분리(1000g, 20℃, 1분)를 통해 RNA를 분리하였다.In more detail, 700 μl of Ribo Ex was dispensed into a 1.5 ml e-tube, and the tissue was well ground using a grinding pestle. Afterwards, 200 μl of chloroform was added and vortexing was performed to remove the phenol component of the supernatant. After centrifugation (12000g at 4℃, 15 minutes), the supernatant was added, and then the RB1 aqueous solution was added to the supernatant, the supernatant and the RB1 solution were mixed well, and then dropped dropwise onto the spin columm to perform centrifugation. (20°C at 10000 g, 1 minute). Thereafter, washing was performed using an aqueous solution of SW1 and an aqueous solution of RNW and RNA was isolated through centrifugation (1000 g, 20°C, 1 minute) by slowly adding 50 µl of free-water.

<실시예 3. cDNA 합성><Example 3. cDNA synthesis>

CycleScript RT premix(bioneer)를 사용하여 cDNA 합성을 하는 rtPCR을 진행하였다. premix에 RNAase free-water를 18㎕ 씩 넣고 실시예 2에서 얻은 RNA를 2㎕ 씩 넣는다. vortexing 과정을 거친 뒤 cDNA를 합성하였다. cDNA 합성 조건은 다음 표 1과 같다.RtPCR was performed for cDNA synthesis using CycleScript RT premix (bioneer). Add 18 µl of RNAase free-water to the premix and add 2 µl of the RNA obtained in Example 2. After the vortexing process, cDNA was synthesized. cDNA synthesis conditions are shown in Table 1 below.

cDNA 합성조건cDNA synthesis conditions StepStep Temp.(℃)Temp.(℃) TimeTime CycleCycle 1One 20℃20℃ 30초30 seconds 1212 22 45℃45℃ 4분4 minutes 33 55℃55℃ 30초30 seconds 44 95℃95℃ 5분5 minutes 1One

이와 같은 방법으로 얻은 cDNA를 스펙트로포토메타(spectrophotometer)를 사용하여 DNA 농도를 측정한 후 200㎍/㎖로 농도를 맞추고 -20℃ 냉동고에 보존하여 사용하였다. The cDNA obtained in this way was measured for DNA concentration using a spectrophotometer, adjusted to a concentration of 200 μg/ml, and stored in a freezer at -20°C.

<실시예 4. 프라이머 합성> <Example 4. Primer synthesis>

본 발명에 사용된 TGF beta의 프라이머는 oligo primer로 합성하여 사용하였으며, primer 염기서열 및 조건은 표 2와 같고, TGF beta의 Genbank No.는 다음과 같다. Primers of TGF beta used in the present invention were synthesized and used as oligo primers, primer sequences and conditions are shown in Table 2, and Genbank No. of TGF beta is as follows.

TGF beta : XM_020097733.1TGF beta: XM_020097733.1

Oligo NAMEOligo NAME ScaleScale PurifictionPurifiction sequence(5' --> 3')sequence(5' --> 3') 증폭산물의
DNA size(b.p.)
Amplification products
DNA size(bp)
1One TGF betaTGF beta 25 nmole25 nmole BioRPBioRP F : TGGAAAGGAACTCGACCAAC
R : AATGGGTCTCCTTCGATGTG
F: TGGAAAGGAACTCGACCAAC
R: AATGGGTCTCCTTCGATGTG
158158
22 beta Actinbeta Actin 25 nmole25 nmole BioRPBioRP F : CGTGCTGTCTTCCCATCCA
R : TCACCAACGTAGCTGTCTTTCTG
F: CGTGCTGTCTTCCCATCCA
R: TCACCAACGTAGCTGTCTTTCTG
200200

<실시예 5. 유전자의 중합효소연쇄반응(PCR) 및 전기영동> <Example 5. Polymerase chain reaction (PCR) and electrophoresis of genes>

강도다리의 cDNA를 각각 디자인한 프라이머를 이용하여 PCR 하였다. PCR premix는 바이오니아 회사의 PyroHotstart Taq PCR premix를 사용하였다. Total volume 은 20㎕로 D.W 16㎕, cDNA 2㎕(200㎍/㎕) 각각의 Primer를 1 ㎕(10 pmole/㎕) 씩 사용하였다. TGF beta의 PCR 조건은 표 3과 같다.PCR was performed using primers designed for each of the cDNAs of the intensity leg. The PCR premix was a PyroHotstart Taq PCR premix from Bionica. The total volume was 20 µL, and 16 µL of DW and 2 µl (200 µg/µl) of cDNA were used for 1 µl (10 pmole/µl) of each primer. PCR conditions for TGF beta are shown in Table 3.

TGF beta PCR 조건TGF beta PCR conditions StepStep Temp.(℃)Temp.(℃) TimeTime CycleCycle Pre-denaturationPre-denaturation 9595 5분5 minutes 1One DenaturationDenaturation 9595 30초30 seconds 4040 AnnealingAnnealing 6060 30초30 seconds ExtensionExtension 7272 30초30 seconds Final elongationFinal elongation 7272 5분5 minutes 1One

증폭된 DNA 는 2% agarose gel 에서 전기영동을 이용해 DNA 증폭 성공여부를 검증하였다. 어류 장의 면역 상태는 TGF beta의 면역화 전/후의 PCR 결과물 사진에서의 band의 intensity를 측정하여 발현 전의 fold 값을 1.0으로 하여 상대값으로 나타내었고, 발현량이 크게 증가하는 것으로 확인되어 TGF beta가 면역화 지표로 이용하기에 바람직함을 알 수 있다. The amplified DNA was tested for success in DNA amplification using electrophoresis on a 2% agarose gel. The immune status of the fish intestine was measured as the intensity of the band in the PCR product picture before/after immunization of TGF beta, and the fold value before expression was expressed as a relative value. It can be seen that it is preferable to use as.

조건Condition 면역화 후의 유전자 발현 정도값 (fold)Gene expression level after immunization (fold) β-actinβ-actin TGF beta-1TGF beta-1 Streptococcus 비즈 투여군 Streptococcus beads administration group 1.01.0 3.53.5 Vibrio harveyi 비즈 투여군 Vibrio harveyi beads group 1.01.0 3.63.6

<실시예 6. 증폭된 염기서열의 확인><Example 6. Confirmation of amplified base sequence>

PCR 증폭을 해 얻은 산물을 재 확인차 바이오니아(주)에 염기서열분석 의뢰하였다. 분석된 염기서열을 대상으로 NCBI(National Center for Biotechnology Information) blast 검색결과를 통하여 각각의 서열이 각 유전자와 100% 일치함을 확인하였다. The product obtained by PCR amplification was subjected to sequencing to Bionica Co., Ltd. for re-identification. Through the NCBI (National Center for Biotechnology Information) blast search results for the analyzed base sequence, it was confirmed that each sequence is 100% identical to each gene.

<실시예 7. 강도다리의 면역화 상태 확인> <Example 7. Confirmation of immunization status of robber legs>

실시예 1에서 FKC(Streptococcus parauberis, Vibrio harveyi) 비즈가 투여된 강도다리가 면역화된 상태임을 확인하기 위해 FKC 투여 강도다리와 비투여군 강도다리의 질병 상태 및 폐사율을 확인하였다. In Example 1, the disease state and mortality of the FKC-administered burglar and non-administered burglar leg were checked to confirm that the burglar leg to which the FKC ( Streptococcus parauberis , Vibrio harveyi ) beads were administered was immunized.

먼저 FKC(Streptococcus parauberis, Vibrio harveyi) 비즈를 각각 실시예 1과 같이 강도다리에 먹여 면역화를 유도하였다. First, FKC ( Streptococcus parauberis , Vibrio harveyi ) beads were fed to the intensity leg as in Example 1 to induce immunization.

면역화 유도군과 비즈 비투여군 강도다리의 질병은 전염력이 있는 Streptococcus parauberis, Vibrio harveyi를 0.1㎖(1×108 cfu/㎖)씩 강도다리에 먹여 유도하였다(Streptococcus parauberis 균은 약독화된 FKC(Streptococcus parauberis)를 먹인 군에 투여하는 방법을 실시함). In the immunization-inducing group and the non-bead- injected group, the disease of the burglar leg was induced by feeding the infectious Streptococcus parauberis and Vibrio harveyi in 0.1 ml (1×10 8 cfu/ml) in each of the burglar legs ( Streptococcus parauberis bacteria were attenuated FKC ( Streptococcus parauberis ) was administered to the fed group).

조건Condition 비즈 비투여군 (%)Beads non-administered (%) 비즈 투여군 (%)Bead administration group (%) Streptococcus parauberis에 대한 질병 유도군Disease-inducing group for Streptococcus parauberis 80%80% 35%35% Vibrio harveyi에 대한 질병 유도군Disease-inducing group for Vibrio harveyi 70%70% 30%30%

상기 표 5를 참고하면, 질병 유도 후 1개월 후의 폐사율이 비즈 투여군에서 현저하게 줄어들어 면역화가 잘 되었음을 확인할 수 있다. Referring to Table 5, it can be confirmed that immunization was well achieved by significantly reducing the mortality rate after 1 month after disease induction in the beads administration group.

FKC(Streptococcus parauberis, Vibrio harveyi) 투여로 인해 폐사율이 현저하게 줄어들었고, 이를 통해 본 발명에서 확인되는 TGF beta 유전자가 면역화를 통해 발현이 증가되는 유전자임을 제시할 수 있다. Mortality was significantly reduced due to FKC ( Streptococcus parauberis, Vibrio harveyi) administration, and it can be suggested that the TGF beta gene identified in the present invention is a gene whose expression is increased through immunization.

한편, 이와 같은 면역화 과정은 실시예 1과 실시예 7에서 사용한 Streptococcus parauberis, Vibrio harveyi 외에 다른 방법으로 분리된 Streptococcus parauberis, Vibrio harveyi 또는, 기탁기관에 기탁된 표준 균주인 Streptococcus parauberis, Vibrio harveyi를 사용할 때도 거의 유사하게 나타났다. On the other hand, this immunization procedure as that of Example 1, Example 7 Streptococcus parauberis used in, Vibrio harveyi besides the separation Alternatively Streptococcus parauberis, Vibrio harveyi or, when using a standard strain of Streptococcus parauberis, Vibrio harveyi deposited with the depository It appeared almost similar.

<110> JUNWON GBI Co., Ltd. <120> Primer set of transforming growth factors beta for detecting immunization of fish} <160> 2 <170> KoPatentIn 3.0 <210> 1 <211> 20 <212> DNA <213> Unknown <220> <223> Platichthys stellatus <400> 1 tggaaaggaa ctcgaccaac 20 <210> 2 <211> 20 <212> DNA <213> Unknown <220> <223> Platichthys stellatus <400> 2 aatgggtctc cttcgatgtg 20 <110> JUNWON GBI Co., Ltd. <120> Primer set of transforming growth factors beta for detecting immunization of fish} <160> 2 <170> KoPatentIn 3.0 <210> 1 <211> 20 <212> DNA <213> Unknown <220> <223> Platichthys stellatus <400> 1 tggaaaggaa ctcgaccaac 20 <210> 2 <211> 20 <212> DNA <213> Unknown <220> <223> Platichthys stellatus <400> 2 aatgggtctc cttcgatgtg 20

Claims (6)

삭제delete 삭제delete 서열번호 1 및 2의 프라이머 세트를 이용하여 수행되는 하기의 강도다리(Platichthys stellatus)의 면역화 확인 방법.
(제1단계) 강도다리에 면역원으로서 포르말린을 처리하여 약독화된 상태인 스트렙트코쿠스 파라우베리스(Streptococcus parauberis) 또는 비브리오 하르베이(Vibrio harveyi)를 투여하는 단계;
(제2단계) 면역원이 투여된 강도다리와 면역원이 비여투된 강도다리의 장을 각각 채취하여 mRNA(messenger Ribonucleic acid)를 추출하고 cDNA(complementary Deoxyribonucleic acid)를 합성하는 단계;
(제3단계) 상기 cDNA와 서열번호 1 및 2의 프라이머 세트를 이용하여 PCR(Polymerase chain reaction)을 수행하는 단계; 및,
(제4단계) 면역원이 투여된 강도다리와 면역원이 비투여된 강도다리에 대해 TGF 베타(TGF beta : XM_020097733.1)의 발현량을 비교하는 단계
Method for confirming immunization of the following intensity leg ( Platichthys stellatus ) performed using the primer set of SEQ ID NOs: 1 and 2.
Step of administering (a first step) of streptavidin attenuated state by treatment of formalin as an immunogen in the leg strength teuko kusu para Ube-less (Streptococcus parauberis) or Vibrio Har bay (Vibrio harveyi);
(Second step) extracting mRNA (messenger ribonucleic acid) and synthesizing cDNA (complementary deoxyribonucleic acid) by extracting the intestine of the intensity leg to which the immunogen was administered and the intensity leg to which the immunogen was not filtered;
(Step 3) performing PCR (Polymerase chain reaction) using the cDNA and the primer set of SEQ ID NOs: 1 and 2; And,
(Step 4) Comparing the expression level of TGF beta (TGF beta: XM_020097733.1) for the intensity leg administered with the immunogen and the intensity leg without administration of the immunogen
삭제delete 제3항에 있어서,
상기 PCR은 실시간 RT-PCR(Real-time reverse transcript polymerase chain reaction) 또는 RT-PCR(Reverse transcript polymerase chain reaction)인 것을 특징으로 하는 어류의 면역화 확인 방법.
According to claim 3,
The PCR is a real-time RT-PCR (Real-time reverse transcript polymerase chain reaction) or RT-PCR (Reverse transcript polymerase chain reaction) characterized in that the immunization method of fish.
삭제delete
KR1020190012152A 2019-01-30 2019-01-30 Primer set of transforming growth factors beta for detecting immunization of fish KR102130010B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020190012152A KR102130010B1 (en) 2019-01-30 2019-01-30 Primer set of transforming growth factors beta for detecting immunization of fish

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020190012152A KR102130010B1 (en) 2019-01-30 2019-01-30 Primer set of transforming growth factors beta for detecting immunization of fish

Publications (1)

Publication Number Publication Date
KR102130010B1 true KR102130010B1 (en) 2020-07-03

Family

ID=71571865

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020190012152A KR102130010B1 (en) 2019-01-30 2019-01-30 Primer set of transforming growth factors beta for detecting immunization of fish

Country Status (1)

Country Link
KR (1) KR102130010B1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013051909A (en) * 2011-09-02 2013-03-21 Univ Of Miyazaki Health checkup method of fish by multiplex rt-pcr using cytokine gene
KR101789182B1 (en) 2016-06-30 2017-10-23 부산대학교 산학협력단 Primer set for diagnosing infection of fish and method for diagnosing infection of fish using the same
KR20180106570A (en) 2017-03-21 2018-10-01 주식회사 코미팜 Method and apparatus for preparing inhibitable vaccine for prevention of stability bacterial disease including protected serum form of new streptococcus paraberis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013051909A (en) * 2011-09-02 2013-03-21 Univ Of Miyazaki Health checkup method of fish by multiplex rt-pcr using cytokine gene
KR101789182B1 (en) 2016-06-30 2017-10-23 부산대학교 산학협력단 Primer set for diagnosing infection of fish and method for diagnosing infection of fish using the same
KR20180106570A (en) 2017-03-21 2018-10-01 주식회사 코미팜 Method and apparatus for preparing inhibitable vaccine for prevention of stability bacterial disease including protected serum form of new streptococcus paraberis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GenBank accession No. XM_020097733 (2017.02.08.)* *
Seyed Hossein Abdollahi et al., Jundishapur J. Microbiol., 8(5), e17802, 2015* *
Tiehui Wang et al., Fish Shellfish Immunol., 35, pp.1703-1718, 2013.* *

Similar Documents

Publication Publication Date Title
Nguyen et al. A formalin-inactivated vaccine provides good protection against Vibrio harveyi infection in orange-spotted grouper (Epinephelus coioides)
Bruno et al. Saprolegnia and other oomycetes.
Campoverde et al. Ontogeny and modulation after PAMPs stimulation of β-defensin, hepcidin, and piscidin antimicrobial peptides in meagre (Argyrosomus regius)
Sayers et al. Gastrointestinal nematode infection in sheep–a review of the alternatives to anthelmintics in parasite control
Thomas et al. Studies on ulcerative disease caused by Aeromonas caviae-like bacterium in Indian catfish, Clarias batrachus (Linn)
Yu et al. Polymeric immunoglobulin receptor in dojo loach (Misgurnus anguillicaudatus): molecular characterization and expression analysis in response to bacterial and parasitic challenge
Zhang et al. Th17-like immune response in fish mucosal tissues after administration of live attenuated Vibrio anguillarum via different vaccination routes
CN101522210A (en) Compositions and methods of enhancing immune responses
EP3071226B1 (en) Fish vaccine
Pennacchi et al. Immune gene expression in the gills of Atlantic salmon (Salmo salar L.) following experimental reinfection with Neoparamoeba perurans
Bodó et al. Identification of novel lumbricin homologues in Eisenia andrei earthworms
WO2015040574A1 (en) Biological control of insects
Jung et al. Gene expression regulation of the TLR9 and MyD88-dependent pathways in rock bream against rock bream iridovirus (RBIV) infection
US9913888B2 (en) Fish vaccine
KR20210052718A (en) Feed additive comprising fermented mealworm and feed composition using the same
KR102130010B1 (en) Primer set of transforming growth factors beta for detecting immunization of fish
KR102186451B1 (en) Primer set of Integrin beta 1 for detecting immunization of fish
Griffin et al. Edwardsiellosis.
CN101376675B (en) Antimicrobial peptide
KR102271052B1 (en) Primer set for Mucin 18, Mucin 2 like and IgM detecting immunization of fish
CN111471107B (en) Anti-coccidiosis multivalent recombinant protein yolk antibody and preparation method and application thereof
CN105121625A (en) Immunogenic composition against aeromonas hydrophila
EP1023453B1 (en) Tgc method for inducting targeted somatic transgenesis
Makridis et al. Use of microalgae bioencapsulated in Artemia during the weaning of Senegalese sole (Solea senegalensis Kaup)
Murphy et al. Aquarium fish dermatologic diseases

Legal Events

Date Code Title Description
GRNT Written decision to grant